Natural Resources for Human Health
eISSN: 2583-1194

Original Research

Received 25 May 2026
Revised 29 June 2026
Accepted 17 July 2026

Natural Resources for Human Health 2026, Vol. 6 (9s): 879–886

KEYWORDS:
rheumatoid arthritis, biological therapy, biologic DMARDs, treatment response, biomarkers, TNF inhibitors, precision medicine, rheumatoid factor, anti-CCP, personalized medicine.

# Predictors of Treatment Response to Biological Medications in Patients with Rheumatoid Arthritis

Dr. Ali bin Mohammmed Asiri[1], Ali yahya Al-Huraishi[2], Yosef shblan Al asmari[3], Turki hamad Alamri[4], abdullah awad alshahrani[5], Saeed Mobasher Mobasher Al Asmari[6], Abdullah Ghazi Ali AlShehri[7], Saad saeed albakhat[8]

[1] Pharmacist
am-assiri@outlook.sa
[2] Pharmacy Technician, Armed Forces Hospital Southern Region, Khamis Mushait, Saudi Arabia
abowassamalhrisi@gmai.com
[3] Pharmacy technician, King Fahad military Hospital, Khamis Mushait
Joseph69478@gmail.com
[4] Pharmacy Technician, Southern Military Hospital, Abha
Turkesh1517@gmail.com
[5] Pharmacy Technician, Armed Forces Hospital in the South, Khamis Mushait
bahrelana@icloud.com
[6] Pharmacy technician, Armed force hospital Southern Region, khamis mushait
S-Alasmari7@hotmail.com
[7] Pharmacy Technician, Armed Forces Hospital - Southern Region, Khamis Mushait
Email address- a.ghazi44@gmail.com
[8] pharmacy technicians, Armed forces south region, khamis mushait
Email address-saad_2002sasa@Hotmail.com

## ABSTRACT:

**Background:** Rheumatoid arthritis (RA) is a chronic systemic autoimmune inflammatory disease characterized primarily by persistent synovitis, progressive joint destruction, functional impairment, and reduced quality of life. Biological disease-modifying antirheumatic drugs (bDMARDs) have substantially improved the management of moderate-to-severe RA, particularly in patients with inadequate responses to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Nevertheless, considerable variability exists in clinical response, treatment persistence, and adverse-event profiles among individual patients.

**Objective:** This review evaluates clinical, demographic, serological, genetic, pharmacological, and lifestyle-related factors associated with treatment response to biological medications in patients with RA. It also discusses the potential role of biomarkers and precision medicine in optimizing biological therapy selection.

**Methods:** A narrative review approach was used to synthesize evidence regarding predictors of response to major biological therapies used for RA, including tumor necrosis factor inhibitors (TNFi), interleukin-6 (IL-6) pathway inhibitors, B-cell-directed therapy, and T-cell costimulation modulators. Particular attention was given to factors that may be applicable to routine clinical practice.

Natural Resources for Human Health
eISSN: 2583-1194

**Results:** Treatment response to biological therapy appears to be influenced by multiple interacting variables rather than a single predictive marker. Important factors include baseline disease activity, disease duration, previous treatment exposure, rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA) status, smoking, obesity, treatment adherence, concomitant methotrexate use, and immunogenicity. Certain predictors may be treatment-specific. For example, seropositivity has been associated with improved responses to some non-TNF biological agents, whereas obesity may negatively influence the effectiveness of some TNF inhibitors.

**Conclusion:** Identification of predictors of biological treatment response may improve individualized treatment selection in RA. However, no single biomarker currently provides sufficient accuracy to independently determine the optimal biological agent. Future strategies combining clinical characteristics, molecular biomarkers, pharmacogenomics, therapeutic drug monitoring, and machine-learning models may facilitate precision medicine in RA.

## 1. INTRODUCTION

Rheumatoid arthritis is a systemic immune-mediated inflammatory disorder affecting approximately 0.5–1% of many adult populations, although prevalence varies considerably according to geographic region, sex, age, ethnicity, and methodology. Persistent inflammation of the synovial membrane may cause cartilage destruction, bone erosion, deformity, disability, and extra-articular complications. RA is also associated with increased cardiovascular, infectious, pulmonary, and metabolic morbidity.

The treatment of RA has changed substantially with the introduction of targeted therapies. Methotrexate remains a central component of initial pharmacological management for many patients. When treatment targets are not achieved despite optimized conventional synthetic DMARD therapy, biological or targeted synthetic DMARDs may be introduced according to disease characteristics, previous treatments, comorbidities, contraindications, and patient preferences.

Biological medications used in RA target specific components of the immune response. Major therapeutic classes include TNF inhibitors such as adalimumab, infliximab, etanercept, certolizumab pegol, and golimumab; IL-6 pathway inhibitors such as tocilizumab and sarilumab; the anti-CD20 monoclonal antibody rituximab; and the T-cell costimulation modulator abatacept.

Despite their effectiveness, biological therapies do not produce an adequate response in every patient. Some patients achieve sustained remission, whereas others demonstrate partial improvement, primary non-response, secondary loss of response, intolerance, or treatment-limiting adverse events.

The ability to predict treatment response before starting a biological agent therefore represents an important clinical objective. Accurate prediction could reduce unnecessary exposure to ineffective drugs, decrease delays in controlling inflammation, minimize irreversible joint damage, and potentially reduce healthcare costs.

## 2. BIOLOGICAL THERAPY AND TREATMENT RESPONSE

Treatment response in RA can be evaluated using several validated measures, including the Disease Activity Score in 28 joints (DAS28), Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI), American College of Rheumatology response criteria, patient-reported outcomes, physical function assessments, and achievement of remission or low disease activity.

A fundamental difficulty in identifying predictors is that RA is biologically heterogeneous. Two patients with apparently similar clinical disease may have substantially different underlying inflammatory pathways.

Furthermore, response predictors may vary between biological drug classes. A factor associated with response to rituximab, for example, cannot automatically be assumed to predict response to TNF inhibition.

## 3. DEMOGRAPHIC PREDICTORS

### 3.1 Age

Age may influence biological treatment outcomes through several mechanisms. Older patients frequently have longer disease duration, greater accumulated joint damage, polypharmacy, immunosenescence, and higher comorbidity burdens.

Although biological medications can remain effective in older adults, comorbidities and adverse-event risks may influence treatment persistence and the overall risk-benefit assessment. Age alone should therefore not be considered an absolute predictor of treatment failure.

### 3.2 Sex

RA is substantially more common among women. Some observational studies have suggested differences in response or remission rates between men and women. However, sex-related associations are inconsistent and may be confounded by differences in pain perception, body composition, disease severity, hormonal factors, and patient-reported outcome components.

Sex is consequently unlikely to be sufficiently predictive when considered independently.

### 3.3 Body Mass Index and Obesity

Obesity is increasingly recognized as a potentially important modifier of treatment response. Adipose tissue is metabolically active and produces adipokines and inflammatory mediators that may contribute to systemic inflammation.

Obesity has been associated in several studies with lower probability of achieving favorable clinical outcomes, particularly with some TNF inhibitors. Pharmacokinetic differences may also contribute, especially for fixed-dose therapies.

Weight management should therefore be viewed as part of comprehensive RA care rather than solely as a cardiovascular intervention.

## 4. DISEASE-RELATED PREDICTORS

### 4.1 Baseline Disease Activity

Baseline disease activity is one of the most frequently studied predictors of treatment outcome. Patients with severe baseline inflammation may demonstrate large absolute improvements after treatment but may still fail to reach remission because their residual disease activity remains elevated.

For this reason, investigators should distinguish between predictors of **change in disease activity** and predictors of **achieving remission or low disease activity**.

### 4.2 Disease Duration

Earlier effective suppression of inflammation generally provides better opportunities to prevent structural damage and preserve function.

Patients with longstanding disease may have irreversible joint destruction and disability that cannot be completely reversed even when inflammatory activity is successfully controlled. This supports contemporary treat-to-target approaches emphasizing early diagnosis and timely escalation of effective therapy.

### 4.3 Previous Biological Treatment

Previous exposure to biological therapies is an important treatment-related predictor. Biologic-naïve patients may have better responses to certain agents than patients who have already failed multiple biological treatments.

Importantly, the reason for previous treatment failure should be considered. Primary non-response may suggest that the targeted inflammatory pathway is not dominant in that patient, whereas secondary loss of response may result from immunogenicity, altered pharmacokinetics, adherence problems, or changes in disease biology.

## 5. SEROLOGICAL PREDICTORS

### 5.1 Rheumatoid Factor

Rheumatoid factor is a well-established diagnostic and prognostic marker in RA. RF-positive disease is often associated with particular clinical phenotypes and may influence response to selected biological therapies.

Seropositivity appears especially relevant for B-cell-directed treatment. Evidence indicates that RF-positive patients may experience better clinical outcomes with rituximab than seronegative patients.

Nevertheless, RF alone should not determine treatment choice because seronegative patients may also respond.

### 5.2 Anti-Citrullinated Protein Antibodies

ACPA, commonly measured clinically using anti-cyclic citrullinated peptide (anti-CCP) assays, is highly relevant to RA pathophysiology and prognosis.

ACPA positivity has been associated with better responses to certain biological agents, particularly abatacept and rituximab in some patient populations. The predictive value may be enhanced when RF and ACPA are considered together.

Serological status therefore represents one of the most clinically accessible potential tools for treatment stratification.

## 6. INFLAMMATORY BIOMARKERS

C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are routinely used to estimate inflammatory activity.

Elevated inflammatory markers can indicate active inflammatory disease and may help distinguish inflammation-driven symptoms from pain arising predominantly from irreversible structural damage, fibromyalgia, or other non-inflammatory mechanisms.

However, CRP and ESR are nonspecific and can be influenced by infection, obesity, age, anemia, and other medical conditions. Their predictive value should therefore be interpreted in combination with clinical findings.

Research has increasingly investigated additional biomarkers, including cytokine profiles, autoantibody signatures, immune-cell phenotypes, transcriptomics, proteomics, and synovial tissue characteristics. These approaches are promising but have not yet produced a universally accepted biomarker capable of reliably selecting one biological drug for an individual patient.

## 7. SMOKING AS A PREDICTOR OF TREATMENT RESPONSE

Smoking is both an environmental risk factor for RA and a potentially modifiable determinant of treatment outcome.

Evidence from observational studies suggests that current smoking may be associated with poorer responses to certain therapies, including TNF inhibitors and methotrexate.

Possible mechanisms include altered immune regulation, increased protein citrullination, persistent systemic inflammation, pharmacokinetic changes, and differences in disease phenotype.

Smoking cessation should therefore form part of comprehensive RA management and may provide benefits beyond treatment response, including reduction of cardiovascular, pulmonary, and malignancy risks.

## 8. CONCOMITANT METHOTREXATE THERAPY

Methotrexate is frequently combined with biological therapy unless contraindicated or poorly tolerated.

Combination therapy may improve clinical effectiveness for some biologics and, importantly, can decrease the development of anti-drug antibodies against certain monoclonal antibodies.

Immunogenicity may reduce circulating biological drug concentrations and contribute to secondary treatment failure. The protective effect of concomitant methotrexate against immunogenicity is therefore clinically important for selected agents.

However, not all biological therapies require methotrexate to the same degree. Treatment should be individualized according to previous response, tolerability, liver function, reproductive considerations, comorbidities, and other relevant factors.

## 9. IMMUNOGENICITY AND THERAPEUTIC DRUG LEVELS

The development of anti-drug antibodies represents an important pharmacological mechanism underlying treatment failure for some biological medications.

Anti-drug antibodies can increase drug clearance, reduce serum concentrations, neutralize therapeutic activity, and occasionally contribute to infusion or injection reactions.

Therapeutic drug monitoring has therefore been investigated as a method of distinguishing pharmacokinetic failure from pharmacodynamic failure.

For example, a patient with low biological drug concentration and detectable anti-drug antibodies may require a different management strategy than a patient with adequate drug concentrations but persistent active disease.

Routine proactive therapeutic drug monitoring is not universally established for RA, but reactive measurement may have value in selected circumstances and remains an active research area.

## 10. TREATMENT ADHERENCE AND PERSISTENCE

An apparent biological treatment failure does not always represent true pharmacological failure.

Poor adherence may occur because of injection discomfort, fear of adverse effects, complicated administration schedules, cost or access problems, inadequate patient education, psychological factors, or misunderstanding of the chronic nature of therapy.

Before classifying a patient as a biological non-responder, clinicians should evaluate adherence, administration technique, interruptions due to infection or surgery, and access to medication.

Pharmacists and nurses can play an important role in detecting adherence barriers, educating patients, monitoring adverse effects, and supporting persistence.

## 11. MAJOR PREDICTORS OF BIOLOGICAL TREATMENT RESPONSE

| Predictor | Potential association with response | Possible clinical implication |
|---|---|---|
| RF/ACPA positivity | May predict better response to selected agents, particularly rituximab and abatacept | Consider serological phenotype when selecting therapy |
| High baseline disease activity | May permit greater absolute improvement but can reduce probability of achieving remission | Interpret improvement and target achievement separately |
| Shorter disease duration | Generally associated with better opportunity for disease control and functional preservation | Encourage early treatment optimization |
| Obesity/high BMI | May reduce response to some biological therapies, particularly certain TNFi | Incorporate weight management and monitor response carefully |
| Current smoking | Frequently associated with poorer treatment outcomes | Strongly encourage smoking cessation |
| Previous biologic failures | Multiple previous failures may decrease probability of subsequent response | Consider mechanism of previous failure when switching |
| Concomitant methotrexate | Can improve response/persistence and decrease immunogenicity with selected biologics | Consider combination therapy when appropriate |

| Predictor | Potential association with response | Possible clinical implication |
|---|---|---|
| Anti-drug antibodies | Can cause low drug concentrations and secondary treatment failure | Consider immunogenicity in unexplained loss of response |
| Good adherence | Increases likelihood of sustained therapeutic exposure and response | Assess adherence before declaring pharmacological failure |
| Comorbidity burden | May influence effectiveness, tolerability and persistence | Individualize drug selection and monitoring |

## 12. TREATMENT-SPECIFIC PREDICTORS

### TNF Inhibitors

TNF inhibitors were among the first biological therapies to transform RA management. Predicting TNFi response remains challenging. Smoking, obesity, long disease duration, high disability, and multiple previous treatment failures have been associated with poorer outcomes in some cohorts.

Concomitant methotrexate can improve outcomes and reduce immunogenicity for some anti-TNF monoclonal antibodies.

### Rituximab

Rituximab targets CD20-positive B lymphocytes. Seropositivity represents one of the more reproducible clinical characteristics associated with response. RF- and/or ACPA-positive patients tend, on average, to demonstrate stronger responses than seronegative patients.

### Abatacept

Abatacept modifies T-cell costimulation through interaction with the CD80/CD86-CD28 pathway. Evidence from clinical and observational studies suggests that ACPA-positive patients, particularly those with higher antibody concentrations in some analyses, may have improved outcomes compared with seronegative patients.

### IL-6 Pathway Inhibition

Tocilizumab and sarilumab inhibit IL-6 signaling and can substantially reduce inflammatory activity. Because IL-6 strongly influences hepatic CRP production, CRP can fall rapidly following IL-6 pathway inhibition.

Clinicians should therefore recognize that composite disease activity scores containing acute-phase reactants may show substantial improvement partly because of the direct biological effect on CRP. Clinical joint assessment and patient-reported outcomes remain important.

## 13. PHARMACOGENOMICS AND GENETIC PREDICTORS

Genetic variation represents an attractive approach to predicting treatment response. Candidate-gene studies and genome-wide association studies have examined polymorphisms associated with TNF signaling, Fc receptors, immune regulation, drug metabolism, and other pathways.

Although several associations have been reported, replication has often been inconsistent across populations. Individual genetic variants generally provide insufficient predictive power for routine clinical decision-making.

The future is more likely to involve polygenic or multi-omic models combining genetic information with clinical, serological, proteomic, transcriptomic, and environmental data.

## 14. ARTIFICIAL INTELLIGENCE AND PRECISION MEDICINE

Artificial intelligence and machine-learning approaches provide an opportunity to integrate large numbers of variables simultaneously.

A future predictive model could potentially incorporate age, sex, BMI, smoking status, disease duration, RF, ACPA, CRP, ESR, previous DMARD exposure, comorbidities, medication adherence, genomic information, drug concentrations, imaging findings, and patient-reported outcomes.

Such models could estimate the probability that an individual patient will respond to different biological mechanisms before treatment begins.

However, AI models require rigorous external validation, diverse patient populations, transparent reporting, clinically meaningful performance, and assessment of bias before routine implementation.

## 15. CLINICAL IMPLICATIONS

Predicting treatment response should not be interpreted as identifying a single laboratory test that determines therapy. Rather, biological selection should involve multidimensional patient assessment.

Before initiating or switching biological therapy, clinicians should consider disease activity, previous treatment history, serological status, comorbidities, infection risk, vaccination status, pregnancy considerations when applicable, smoking, body weight, patient preference, adherence, route of administration, and treatment accessibility.

After treatment initiation, patients should be reassessed using standardized disease activity measures according to a treat-to-target strategy.

Lack of response should trigger systematic evaluation rather than automatic switching. Clinicians should determine whether persistent symptoms represent active inflammation, structural joint damage, central pain sensitization, fibromyalgia, non-adherence, inadequate drug exposure, immunogenicity, or an alternative diagnosis.

## 16. ROLE OF THE MULTIDISCIPLINARY TEAM

Optimal biological therapy requires collaboration among rheumatologists, pharmacists, nurses, primary-care clinicians, and other healthcare professionals.

Clinical pharmacists can contribute through medication reconciliation, interaction assessment, adherence evaluation, patient education, vaccination review, pharmacovigilance, monitoring of laboratory abnormalities, and appropriate medication storage counseling.

Nurses can support administration training, symptom monitoring, infection education, and early identification of adverse events.

Multidisciplinary management is particularly important for patients receiving long-term immunomodulatory therapy because treatment effectiveness and safety must be considered simultaneously.

## 17. FUTURE RESEARCH DIRECTIONS

Future research should prioritize prospective, adequately powered studies comparing predictive models across different biological mechanisms.

Particular attention should be given to multi-biomarker approaches rather than isolated predictors. Integration of clinical phenotyping with genomics, transcriptomics, proteomics, metabolomics, synovial tissue analysis, imaging, therapeutic drug monitoring, and patient-generated health data may improve predictive accuracy.

Real-world registries will remain important because randomized clinical trials may not fully represent older adults, patients with multiple comorbidities, or individuals with extensive previous treatment exposure.

Future studies should also evaluate whether prediction-guided therapy produces better clinical outcomes and is cost-effective compared with conventional trial-and-error treatment selection.

## 18. CONCLUSION

Biological therapies have transformed the management of rheumatoid arthritis, yet substantial interpatient variability in response remains a major clinical challenge. Treatment response is determined by a complex interaction among patient characteristics, disease phenotype, serological status, lifestyle factors, pharmacological exposure, immunogenicity, and treatment adherence.

RF and ACPA positivity may provide useful predictive information for selected biological therapies, particularly rituximab and abatacept. Obesity, smoking, long disease duration, multiple previous biological failures, poor adherence, and anti-drug antibody development may contribute to less favorable outcomes in certain settings. Concomitant methotrexate can enhance treatment effectiveness and reduce immunogenicity for selected biological agents.

Nevertheless, no individual clinical characteristic or biomarker currently possesses sufficient predictive accuracy to independently determine biological therapy selection for every patient with RA. The future of RA management is therefore likely to involve integrated precision-medicine models combining clinical variables with molecular biomarkers, pharmacogenomics, therapeutic drug monitoring, and artificial intelligence. Such approaches may eventually allow clinicians to select the therapy with the greatest probability of effectiveness and acceptable safety for each individual patient.

## REFERENCES

[1] Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. *Ann Rheum Dis.* 2023;82(1):3–18.

[2] Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Care Res (Hoboken).* 2021;73(7):924–939.

[3] Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. *Lancet.* 2016;388(10055):2023–2038.

[4] Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. *JAMA.* 2018;320(13):1360–1372.

[5] McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. *N Engl J Med.* 2011;365(23):2205–2219.

[6] Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate. *Ann Rheum Dis.* 2010;69(9):1629–1635.

[7] Isaacs JD, Cohen SB, Emery P, et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response. *Ann Rheum Dis.* 2013;72(3):329–336.

[8] Jani M, Barton A, Warren RB, Griffiths CEM, Chinoy H. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. *Rheumatology (Oxford).* 2014;53(2):213–222.

[9] Hyrich KL, Watson KD, Silman AJ, Symmons DPM. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. *Rheumatology (Oxford).* 2006;45(12):1558–1565.

[10] Potter C, Hyrich KL, Tracey A, et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity with response to anti-TNF therapy in rheumatoid arthritis. *Ann Rheum Dis.* 2009;68(1):69–74.

[11] Daïen CI, Morel J. Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine. *Mediators Inflamm.* 2014;2014:386148.

[12] Wijbrandts CA, Tak PP. Prediction of response to targeted treatment in rheumatoid arthritis. *Mayo Clin Proc.* 2017;92(7):1129–1143.

[13] Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. *Ann Rheum Dis.* 2016;75(1):3–15.

[14] Gottenberg JE, Courvoisier DS, Hernandez MV, et al. Brief report: association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept. *Arthritis Rheumatol.* 2016;68(6):1346–1352.

[15] Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. *Lancet.* 2017;389(10086):2338–2348.